Dyne Therapeutics, Inc. (BX:DYN) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: US$375.15M · US$20.5 a share · Morgan Stanley +5 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), LifeSci Capital (co-lead), Raymond James (co-lead), Jones | Jul 22, 2026 |
| Public offering of common stock Closed: US$402.5M raised · US$18.44 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead) | Dec 11, 2025 |
| Public offering of common stock Closed: US$230M raised · US$8.25 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Jones | Jul 2, 2025 |
| At-the-market programme of common stock Closed: US$140.6M raised Use of proceeds: To fund operations, together with existing cash, at least into the second half of 2026 | Feb 27, 2025 |